- Conditions
- Stress Fracture of Tibia or Fibula
- Interventions
- Teriparatide, Placebos
- Drug
- Lead sponsor
- University of South Carolina
- Other
- Eligibility
- Not listed
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Columbia, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Bipolar Disorder
- Interventions
- Magnetic Resonance Imaging, Psychiatric testing, Eye-Tracking, Neuropsychology Evaluation
- Other
- Lead sponsor
- Jennifer Sweet
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Malocclusion
- Interventions
- EXD-959 Bracket System
- Device
- Lead sponsor
- 3M
- Industry
- Eligibility
- 11 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 5
- States / cities
- Culver City, California • Wellington, Florida • Northfield, Minnesota + 2 more
- Conditions
- Tooth Loss
- Interventions
- Control Collagen Wound Dressing, Test Collagen Matrix
- Device
- Lead sponsor
- McGuire Institute
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Fenton, Michigan
- Conditions
- Glaucoma
- Interventions
- Rho-Kinase Inhibitor (AR-12286)
- Drug
- Lead sponsor
- New York Glaucoma Research Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Fluid Retention, Beverage Hydration Index, Hydration Status
- Interventions
- Test product 1, Test product 2, Placebo
- Other
- Lead sponsor
- Liquid I.V.
- Other
- Eligibility
- 18 Years to 35 Years · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Treatment of Sweet Taste Receptors Without or With an Oral Rinse of Ibuprofen Solution in Healthy Participants, Treatment of Sweet Taste Receptors Without or With an Oral Rinse of Naproxen Solution in Healthy Participants
- Interventions
- Inhibition of Sweet Taste by Ibuprofen Oral Rinses, Inhibition of Sweet Taste by Naproxen Oral Rinses
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Breast Carcinoma, Refractory Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Nodal Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Belinostat, Carfilzomib, Copanlisib Hydrochloride, Daratumumab, Fludeoxyglucose F-18, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Nivolumab, Obinutuzumab, Pembrolizumab, Positron Emission Tomography, Rituximab, Romidepsin, Saline, Trastuzumab
- Drug · Biological · Other + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Obesity, Insulin Resistance
- Interventions
- Fat biopsy during scheduled abdominal surgery, Fat Aspiration, Fish Oil Supplement
- Procedure · Dietary Supplement
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 30 Years to 50 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Growth Hormone Deficiency
- Interventions
- GHRH/arginine stimulation testing
- Procedure
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 5 Years to 40 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Transfusion Related Complication
- Interventions
- SNO, Normal Saline, Red Blood Cell
- Drug
- Lead sponsor
- James Reynolds
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- AML (Acute Myeloid Leukemia), Multiple Myeloma Refractory
- Interventions
- Soursop tea
- Biological
- Lead sponsor
- Roger Strair
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Camden, New Jersey
- Conditions
- Breast Cancer
- Interventions
- Non-contrast DWI, Non-contrast MRI
- Device
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 269 participants
- Timeline
- 2018 – 2029
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Seattle, Washington
- Conditions
- Hearing Loss
- Interventions
- Hearing Aid
- Device
- Lead sponsor
- University of Nebraska Lincoln
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 209 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Matching Placebo, Nintedanib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 11
- States / cities
- Danbury, Connecticut • Sarasota, Florida • Skokie, Illinois + 8 more
- Conditions
- Irregular; Contour of Cornea
- Interventions
- contact lens insertion solution
- Device
- Lead sponsor
- Jennifer Fogt
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Aging Well, Walking, Difficulty, Hyperemia
- Interventions
- Home-based leg heat therapy, Home-based sham therapy
- Other
- Lead sponsor
- University of North Texas Health Science Center
- Other
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Cystic Fibrosis
- Interventions
- Candy Glucose Tolerance Test
- Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pediatric Low-grade Gliomas
- Interventions
- Wave-CAIPI
- Other
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 0 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2028
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
- Interventions
- Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70%, Insulin Suppression Test (IST)
- Drug · Diagnostic Test
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Mental Health, Conflict
- Interventions
- Parent-child intervention, Self-study Intervention
- Behavioral
- Lead sponsor
- University of Notre Dame
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 1,800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 3
- States / cities
- Fort Wayne, Indiana • Indianapolis, Indiana • Notre Dame, Indiana
- Conditions
- Dementia, Parkinsonism, Mild Cognitive Impairment, REM Sleep Behavior Disorder
- Interventions
- I-123 Ioflupane solution injection prior to SPECT scan (DaTscan), Single photon emission computed tomography (SPECT) scan
- Drug · Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Sunburn
- Interventions
- 6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation, 6% Bemotrizinol (BEMT) dispersion in petrolatum, Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT, Petrolatum vehicle, 0.9% Saline, Sodium Lauryl Sulfate 0.1% (SLS), Undosed patch
- Drug · Other
- Lead sponsor
- dsm-firmenich Switzerland AG
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 224 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Piscataway, New Jersey
- Conditions
- Obesity
- Interventions
- Exendin 9-39 and Sitagliptin, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York